The Department of Defense, through the Military Medical Research and Development program (CFDA 12.420), awarded a $613,125 project grant to The University of Texas MD Anderson Cancer Center on February 1, 2025. The grant will support the development of EGFRXHER3 bispecific CAR-T cells for targeting EGFR tyrosine kinase inhibitor drug-tolerant persister cells, with a planned completion date of January 31, 2028. As a prominent research university and comprehensive cancer treatment center, MD Anderson Cancer Center has a track record of conducting innovative cancer research, including preclinical studies, clinical trials, and translational research, funded through prime and subrecipient federal grants from agencies like the National Institutes of Health and Department of Defense.
Generated 3/4/25, 4:41 AM